Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 with Nab-Paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT01839487Phase 2Completed
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- May 2013
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC), sponsored by Halozyme Therapeutics, Inc.. Started May 2013; status: completed.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01839487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839487.